Kudo M - Search Results

1

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Zhu AX, et al. Among authors: kudo m. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Lancet Oncol. 2018. PMID: 29875066 Clinical Trial.

2

Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S. Takahashi S, et al. Among authors: kudo m. Oncology. 2007;72 Suppl 1:98-103. doi: 10.1159/000111714. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087189

3

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study.

Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y, Ueshima K. Kudo M, et al. Oncology. 2007;72 Suppl 1:132-8. doi: 10.1159/000111719. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087194

4

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:1-12. doi: 10.1159/000181865. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092266 Review.

5

Epidemiology of hepatocellular carcinoma in Japan and Korea. A review.

Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS; Organizing Committee of Japan-Korea Liver Symposium. Kim SR, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:13-6. doi: 10.1159/000173419. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092267

6

Impact of interferon therapy after curative treatment of hepatocellular carcinoma.

Kudo M. Kudo M. Oncology. 2008;75 Suppl 1:30-41. doi: 10.1159/000173422. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092270

7

Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.

Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Kitai S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:83-90. doi: 10.1159/000173428. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092276

8

PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.

Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, Ueshima K. Takahashi S, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:91-8. doi: 10.1159/000173429. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092277

9

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.

Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H. Ueshima K, et al. Among authors: kudo m. Oncology. 2008;75 Suppl 1:106-13. doi: 10.1159/000173431. Epub 2008 Dec 17. Oncology. 2008. PMID: 19092279

10

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Kudo M. Kudo M. Int J Clin Oncol. 2010 Jun;15(3):242-55. doi: 10.1007/s10147-010-0089-y. Epub 2010 May 28. Int J Clin Oncol. 2010. PMID: 20509038 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,478 results

Search Page